OptiNose

NASDAQGS:OPTN

ABD / Sağlık Hizmetleri / İlaç

Genel Bakış

Haberler

5 Yıllık Finansal Veriler

Hisse Fiyatı

9,17 USD


Key Metrics	Latest
Total Revenue	78,226 M
Adjusted EBITDA	-16,028 M
EBITDA Margin	-20,5%
Net Profit Margin	-27,5%
Total Assets	128,8 M
Total Debt	162,8 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	49.12	74.65	76.28	70.99	78.23	78.23	70.99	78.23
% Growth		0.52	0.02	(0.07)	0.10			0.10

Adjusted EBITDA	(85.76)	(65.80)	(55.36)	(22.35)	(16.03)	(16.03)	(22.35)	(16.03)
% Margin	(1.75)	(0.88)	(0.73)	(0.31)	(0.20)	(0.20)	(0.31)	(0.20)

Adjusted EBIT	(87.22)	(66.45)	(55.90)	(22.75)	(16.32)	(16.32)	(22.75)	(16.32)
% Margin	(1.78)	(0.89)	(0.73)	(0.32)	(0.21)	(0.21)	(0.32)	(0.21)

Adjusted Net Income	(99.79)	(82.35)	(74.83)	(35.48)	(21.54)	(21.54)	(35.48)	(21.54)
% Margin	(2.03)	(1.10)	(0.98)	(0.50)	(0.28)	(0.28)	(0.50)	(0.28)

Adjusted Basic EPS	(31.01)	(21.73)	(13.07)	(4.75)	(2.12)	(2.12)	(4.75)	(2.12)

Destekleyen Hesaplamalar

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Press Release
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	49	75	76	71	78	78	71	78
% Growth	NA	52.0%	2.2%	-6.9%	10.2%			10.2%

Cost of Revenue	(8)	(9)	(9)	(9)	(7)	(7)	(9)	(7)
Gross Profit	42	66	67	62	71	71	62	71
% Revenue	84.7%	87.7%	87.9%	87.8%	90.8%	90.8%	87.8%	90.8%

Research and Development	(23)	(25)	(15)	(5)	(4)	(4)	(5)	(4)
Selling and Marketing	0	0	0	0	0	0	0	0
General and Admin	(105)	(107)	(108)	(80)	(83)	(83)	(80)	(83)
Other Inc / (Exp)	0	0	(3)	4	(5)	(5)	4	(5)
Total Operating Exp	(129)	(132)	(126)	(81)	(93)	(93)	(81)	(93)

Operating Income	(87)	(66)	(59)	(18)	(22)	(22)	(18)	(22)
% Revenue	-177.6%	-88.9%	-76.7%	-26.0%	-27.5%	-27.5%	-26.0%	-27.5%

Interest Expense	(13)	(16)	(16)	(17)	0	0	(17)	0
Pre-tax Income	(100)	(82)	(75)	(35)	(22)	(22)	(35)	(22)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	0	0	0	0	0	0	0	0
Net Income to Company	(100)	(82)	(75)	(35)	(22)	(22)	(35)	(22)
% Margin	-203.2%	-110.2%	-98.1%	-50.0%	-27.5%	-27.5%	-50.0%	-27.5%

Minority Interest in Earnings	0	0	0	0	0	0	0	0
Net Income to Stockholders	(100)	(82)	(75)	(35)	(22)	(22)	(35)	(22)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	(100)	(82)	(75)	(35)	(22)	(22)	(35)	(22)
% Margin	-203.2%	-110.2%	-98.1%	-50.0%	-27.5%	-27.5%	-50.0%	-27.5%

As Reported
Basic EPS (Continuing Ops)	(31.01)	(21.71)	(13.07)	(4.75)	(2.12)	(2.12)	(4.75)	(2.12)
Diluted EPS (Continuing Ops)	(31.01)	(21.71)	(13.07)	(4.75)	(2.12)	(2.12)	(4.75)	(2.12)

WA Basic Shares Out.	3.22	3.79	5.73	7.47	10.16	10.16	7.47	10.16
WA Diluted Shares Out.	3.22	3.79	5.73	7.47	10.16	10.16	7.47	10.16

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(100)	(82)	(75)	(35)	(22)	(22)	(35)	(22)
Addback: Net Interest Expense	13	16	16	17	0	0	17	0
Addback: Other Non Operating Expenses, Total	0	(0)	3	(4)	5	5	(4)	5
Addback: Depreciation & Amortization	1	1	1	0	0	0	0	0
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	(0)	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	0	0	0	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	0	0	0	0
Adjusted EBITDA	(86)	(66)	(55)	(22)	(16)	(16)	(22)	(16)
% Margin	-174.6%	-88.1%	-72.6%	-31.5%	-20.5%	-20.5%	-31.5%	-20.5%

Adjusted EBIT	(87)	(66)	(56)	(23)	(16)	(16)	(23)	(16)
% Margin	-177.6%	-89.0%	-73.3%	-32.0%	-20.9%	-20.9%	-32.0%	-20.9%

Adjusted Net Income Reconciliation
Net Income to Company	(100)	(82)	(75)	(35)	(22)	(22)	(35)	(22)
Addback: Unusual Items	0	(0)	0	0	0	0	0	0
Less: Tax Benefit of Unusual Items (26%)	0	0	0	0	0	0	0	0
Adjusted Net Income	(100)	(82)	(75)	(35)	(22)	(22)	(35)	(22)
% Margin	-203.2%	-110.3%	-98.1%	-50.0%	-27.5%	-27.5%	-50.0%	-27.5%

Yüklenme Hatası

OptiNose

NASDAQGS:OPTN

ABD / Sağlık Hizmetleri / İlaç

5 Yıllık Finansal Veriler